The role of trastuzumab in early stage breast cancer: current data and treatment recommendations (Q31120100)

29 June 2017

1 reference

title

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations (English)

1 reference

29 June 2017

1 reference

2

Hope S Rugo

1 reference

29 June 2017

Amy Lin

1

1 reference

29 June 2017

1 February 2007

1 reference

Current Treatment Options in Oncology

29 June 2017

1 reference

29 June 2017

8

1 reference

29 June 2017

1

1 reference

29 June 2017

47-60

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-007-0008-2

29 June 2017

0 references

cites work

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-007-0008-2

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-007-0008-2

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

12 December 2020

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

12 December 2020

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

12 December 2020

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

1 reference

12 December 2020

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

12 December 2020

The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review

1 reference

12 December 2020

The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3

1 reference

12 December 2020

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

12 December 2020

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

Mechanism of action of trastuzumab and scientific update

1 reference

12 December 2020

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

1 reference

12 December 2020

ErbB2 is essential in the prevention of dilated cardiomyopathy.

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

HER2 as a predictor of therapeutic response in breast cancer

1 reference

12 December 2020

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

1 reference

12 December 2020

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

12 December 2020

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

12 December 2020

Multi-agent chemotherapy for early breast cancer.

1 reference

12 December 2020

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

1 reference

12 December 2020

Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach.

1 reference

12 December 2020

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

1 reference

12 December 2020

HER-2/neu oncogene amplification and expression in breast and ovarian cancers

1 reference

12 December 2020

Trastuzumab and breast cancer: developments and current status

1 reference

12 December 2020

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

HER2 therapy: molecular mechanisms of trastuzumab resistance.

1 reference

12 December 2020

Clinical cardiac tolerability of trastuzumab

1 reference

12 December 2020

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

12 December 2020

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

12 December 2020

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

12 December 2020

10.1007/S11864-007-0008-2

Identifiers

DOI

1 reference

PubMed ID

17660958

Dimensions Publication ID

29 June 2017

0 references

1 reference

PubMed ID

17660958